Prime Medicine (PRME) Competitors $3.72 +0.32 (+9.41%) Closing price 04:00 PM EasternExtended Trading$3.79 +0.07 (+1.85%) As of 05:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PRME vs. ARQT, DYN, VCEL, SRPT, APGE, BEAM, TWST, IMCR, CDTX, and AUPHShould you be buying Prime Medicine stock or one of its competitors? The main competitors of Prime Medicine include Arcutis Biotherapeutics (ARQT), Dyne Therapeutics (DYN), Vericel (VCEL), Sarepta Therapeutics (SRPT), Apogee Therapeutics (APGE), Beam Therapeutics (BEAM), Twist Bioscience (TWST), Immunocore (IMCR), Cidara Therapeutics (CDTX), and Aurinia Pharmaceuticals (AUPH). These companies are all part of the "pharmaceutical products" industry. Prime Medicine vs. Its Competitors Arcutis Biotherapeutics Dyne Therapeutics Vericel Sarepta Therapeutics Apogee Therapeutics Beam Therapeutics Twist Bioscience Immunocore Cidara Therapeutics Aurinia Pharmaceuticals Arcutis Biotherapeutics (NASDAQ:ARQT) and Prime Medicine (NYSE:PRME) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, institutional ownership, risk, media sentiment, dividends, analyst recommendations and profitability. Do analysts prefer ARQT or PRME? Arcutis Biotherapeutics presently has a consensus price target of $19.80, suggesting a potential upside of 15.45%. Prime Medicine has a consensus price target of $8.92, suggesting a potential upside of 139.70%. Given Prime Medicine's higher probable upside, analysts plainly believe Prime Medicine is more favorable than Arcutis Biotherapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Arcutis Biotherapeutics 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.86Prime Medicine 0 Sell rating(s) 3 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.75 Which has more risk & volatility, ARQT or PRME? Arcutis Biotherapeutics has a beta of 1.93, meaning that its share price is 93% more volatile than the S&P 500. Comparatively, Prime Medicine has a beta of 2.39, meaning that its share price is 139% more volatile than the S&P 500. Does the media favor ARQT or PRME? In the previous week, Arcutis Biotherapeutics had 10 more articles in the media than Prime Medicine. MarketBeat recorded 13 mentions for Arcutis Biotherapeutics and 3 mentions for Prime Medicine. Arcutis Biotherapeutics' average media sentiment score of 0.82 beat Prime Medicine's score of 0.22 indicating that Arcutis Biotherapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arcutis Biotherapeutics 7 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Prime Medicine 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Which has preferable valuation and earnings, ARQT or PRME? Arcutis Biotherapeutics has higher revenue and earnings than Prime Medicine. Arcutis Biotherapeutics is trading at a lower price-to-earnings ratio than Prime Medicine, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioArcutis Biotherapeutics$196.54M10.46-$140.04M-$0.75-22.87Prime Medicine$4.96M100.91-$198.13M-$1.56-2.38 Is ARQT or PRME more profitable? Prime Medicine has a net margin of 0.00% compared to Arcutis Biotherapeutics' net margin of -35.40%. Arcutis Biotherapeutics' return on equity of -62.62% beat Prime Medicine's return on equity.Company Net Margins Return on Equity Return on Assets Arcutis Biotherapeutics-35.40% -62.62% -25.16% Prime Medicine N/A -107.87%-74.97% Do insiders & institutionals believe in ARQT or PRME? 70.4% of Prime Medicine shares are held by institutional investors. 9.4% of Arcutis Biotherapeutics shares are held by company insiders. Comparatively, 22.7% of Prime Medicine shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. SummaryArcutis Biotherapeutics beats Prime Medicine on 9 of the 17 factors compared between the two stocks. Get Prime Medicine News Delivered to You Automatically Sign up to receive the latest news and ratings for PRME and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PRME and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PRME vs. The Competition Export to ExcelMetricPrime MedicineBiological Products IndustryMedical SectorNYSE ExchangeMarket Cap$500.62M$284.31M$5.78B$21.32BDividend YieldN/AN/A6.67%3.52%P/E Ratio-1.81N/A75.6729.64Price / Sales100.91474.43553.7449.94Price / CashN/A22.4437.1124.13Price / Book2.7210.9411.444.55Net Income-$198.13M-$111.61M$3.28B$999.70M7 Day Performance14.81%2.05%0.84%0.55%1 Month Performance-14.87%0.75%7.15%5.67%1 Year Performance-0.80%-14.28%59.66%15.62% Prime Medicine Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PRMEPrime Medicine3.5131 of 5 stars$3.72+9.4%$8.92+139.7%-11.9%$500.62M$4.96M-1.81234ARQTArcutis Biotherapeutics1.1802 of 5 stars$15.69-1.8%$19.80+26.2%+55.0%$1.88B$196.54M-20.92150Positive NewsInsider TradeDYNDyne Therapeutics3.6823 of 5 stars$13.00+3.3%$34.07+162.1%-60.8%$1.85BN/A-3.37100News CoveragePositive NewsVCELVericel2.3325 of 5 stars$35.79-3.3%$60.33+68.6%-29.8%$1.81B$237.22M298.27300Positive NewsSRPTSarepta Therapeutics4.8368 of 5 stars$18.06-10.7%$43.50+140.9%-86.3%$1.76B$1.90B-20.761,372Positive NewsHigh Trading VolumeAPGEApogee Therapeutics3.1418 of 5 stars$36.94-3.5%$99.00+168.0%-20.9%$1.70BN/A-8.9491News CoveragePositive NewsBEAMBeam Therapeutics2.5336 of 5 stars$16.44-1.2%$48.45+194.7%-23.0%$1.66B$63.52M-3.65510News CoveragePositive NewsTWSTTwist Bioscience3.9073 of 5 stars$27.39-4.2%$49.40+80.4%-35.2%$1.65B$312.97M-18.89990Positive NewsIMCRImmunocore1.8826 of 5 stars$32.59-1.0%$56.89+74.6%-3.0%$1.64B$310.20M-81.48320News CoveragePositive NewsCDTXCidara Therapeutics3.8725 of 5 stars$64.13-3.4%$64.14+0.0%+473.8%$1.63BN/A-5.7690News CoveragePositive NewsAUPHAurinia Pharmaceuticals2.983 of 5 stars$12.14-1.1%$12.00-1.2%+79.5%$1.60B$260.11M28.23300Positive News Related Companies and Tools Related Companies Arcutis Biotherapeutics Alternatives Dyne Therapeutics Alternatives Vericel Alternatives Sarepta Therapeutics Alternatives Apogee Therapeutics Alternatives Beam Therapeutics Alternatives Twist Bioscience Alternatives Immunocore Alternatives Cidara Therapeutics Alternatives Aurinia Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:PRME) was last updated on 9/5/2025 by MarketBeat.com Staff From Our PartnersWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredOne tiny company just cracked Google’s $19B problemFor decades, this “AI metal” was trapped in labs, too slow and expensive to ever reach mass production. The...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Prime Medicine, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Prime Medicine With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
